{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:22:40Z","timestamp":1789053760759,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T00:00:00Z","timestamp":1558396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T00:00:00Z","timestamp":1558396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Thyroid cancer is commonly seen in the clinic with a rapidly increasing incidence globally. COX-2 overexpression correlates with the pathologic type of thyroid carcinoma, and it has been suggested that COX-2 overexpression is associated with a poor prognosis. However, little is known about its upstream regulatory mechanism. Bioinformatics suggested that transcription factor AP-2 beta (TFAP2B) might specifically bind to the COX-2 promoter, which was confirmed by biotin-labeled COX-2 promoter pulldown and luciferase reporter assays. We performed western blot and immunohistochemical staining to detect the expression of TFAP2B\/COX-2 in thyroid cancer tissues (T) and the matched adjacent noncarcinoma tissues (ANT), and investigated the relationship between TFAP2B\/COX-2 expression and clinical pathological factors in thyroid cancer patients. Afterward, MTS, colony formation, cell-apoptosis assay, transwell-invasion and scratch assays were performed to examine the proliferation, apoptosis, invasion, and migration of thyroid cancer cells with TFAP2B knocked down or overexpressed. The mouse xenograft experiment was performed to study in vivo the proliferation of thyroid cancer cells with TFAP2B knocked down or overexpressed. We found that TFAP2B bound to the promoter of COX-2 to activate its expression. Western blot and immunohistochemistry showed that TFAP2B\/COX-2 was highly expressed in thyroid cancer, and high TFAP2B and COX-2 expression was associated with aggressive clinicopathological features in thyroid cancer. TFAP2B mediated thyroid cancer cell proliferation, apoptosis, invasion, and migration via the COX-2 signaling pathway in vitro and in vivo. TFAP2B bound to the promoter of COX-2 to activate its expression, indicating that TFAP2B is a critical regulatory molecule in the COX-2 signaling pathway that promoted tumor progression in thyroid cancer.<\/jats:p>","DOI":"10.1038\/s41419-019-1600-7","type":"journal-article","created":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T11:06:56Z","timestamp":1558436816000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["TFAP2B overexpression contributes to tumor growth and progression of thyroid cancer through the COX-2 signaling pathway"],"prefix":"10.1038","volume":"10","author":[{"given":"Xiaoyan","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huayong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhipeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongyuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingbo","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianrun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weichao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuguo","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,21]]},"reference":[{"key":"1600_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2018. CA Cancer J. Clin. 68, 7\u201330 (2018).","journal-title":"CA Cancer J. Clin."},{"key":"1600_CR2","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1001\/jamaoto.2014.1","volume":"140","author":"L Davies","year":"2014","unstructured":"Davies, L. & Welch, H. G. Current thyroid cancer trends in the United States. JAMA Otolaryngol. Head Neck Surg. 140, 317\u2013322 (2014).","journal-title":"JAMA Otolaryngol. Head Neck Surg."},{"key":"1600_CR3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.4132\/KoreanJPathol.2012.46.1.55","volume":"46","author":"YA Kim","year":"2012","unstructured":"Kim, Y. A., Chang, M., Park, Y. J. & Kim, J. E. Detection of survivin and COX-2 in thyroid carcinoma: anaplastic carcinoma shows overexpression of nuclear survivin and low COX-2 expression. Korean J. Pathol. 46, 55\u201360 (2012).","journal-title":"Korean J. Pathol."},{"key":"1600_CR4","first-page":"2948467","volume":"2017","author":"YX Wang","year":"2017","unstructured":"Wang, Y. X. et al. HPV16 E6 promotes breast cancer proliferation via upregulation of COX-2 expression. Biomed. Res. Int. 2017, 2948467 (2017).","journal-title":"Biomed. Res. Int."},{"key":"1600_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0186900","volume":"12","author":"Z Zhang","year":"2017","unstructured":"Zhang, Z. et al. XRCC5 cooperates with p300 to promote cyclooxygenase-2 expression and tumor growth in colon cancers. PLoS One 12, e0186900 (2017).","journal-title":"PLoS One"},{"key":"1600_CR6","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/bcr1678","volume":"9","author":"LR Howe","year":"2007","unstructured":"Howe, L. R. Inflammation and breast cancer cyclooxygenase\/prostaglandin signaling and breast cancer. Breast Cancer Res. 9, 210 (2007).","journal-title":"Breast Cancer Res."},{"key":"1600_CR7","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1002\/pros.10152","volume":"53","author":"H Fujita","year":"2002","unstructured":"Fujita, H. et al. Cyclooxygenase-2 promotes prostate cancer progression. Prostate 53, 232\u2013240 (2002).","journal-title":"Prostate"},{"key":"1600_CR8","first-page":"1317","volume":"23","author":"WK Leung","year":"2003","unstructured":"Leung, W. K. et al. Cyclooxygenase-2 upregulates vascular endothelial growth factor expression and angiogenesis in human gastric carcinoma. Int. J. Oncol. 23, 1317\u20131322 (2003).","journal-title":"Int. J. Oncol."},{"key":"1600_CR9","first-page":"4356","volume":"59","author":"MA Molina","year":"1999","unstructured":"Molina, M. A., Sitja-Arnau, M., Lemoine, M. G., Frazier, M. L. & Sinicrope, F. A. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res. 59, 4356\u20134362 (1999).","journal-title":"Cancer Res."},{"key":"1600_CR10","doi-asserted-by":"publisher","first-page":"4113","DOI":"10.3748\/wjg.v17.i36.4113","volume":"17","author":"R Talar-Wojnarowska","year":"2011","unstructured":"Talar-Wojnarowska, R. et al. Role of cyclooxygenase-2 gene polymorphisms in pancreatic carcinogenesis. World J. Gastroenterol. 17, 4113\u20134117 (2011).","journal-title":"World J. Gastroenterol."},{"key":"1600_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2016.07.016","volume":"381","author":"C Yi","year":"2016","unstructured":"Yi, C. et al. Cleavage and polyadenylation specific factor 4 targets NF-kappaB\/cyclooxygenase-2 signaling to promote lung cancer growth and progression. Cancer Lett. 381, 1\u201313 (2016).","journal-title":"Cancer Lett"},{"key":"1600_CR12","doi-asserted-by":"publisher","first-page":"237","DOI":"10.7150\/ijms.4173","volume":"9","author":"B Ji","year":"2012","unstructured":"Ji, B., Liu, Y., Zhang, P., Wang, Y. & Wang, G. COX-2 expression and tumor angiogenesis in thyroid carcinoma patients among northeast Chinese population-result of a single-center study. Int. J. Med. Sci. 9, 237\u2013242 (2012).","journal-title":"Int. J. Med. Sci."},{"key":"1600_CR13","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1677\/erc.1.01114","volume":"13","author":"P Siironen","year":"2006","unstructured":"Siironen, P. et al. VEGF-C and COX-2 expression in papillary thyroid cancer. Endocr. Relat. Cancer 13, 465\u2013473 (2006).","journal-title":"Endocr. Relat. Cancer"},{"key":"1600_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2005-6-13-246","volume":"6","author":"D Eckert","year":"2005","unstructured":"Eckert, D., Buhl, S., Weber, S., Jager, R. & Schorle, H. The AP-2 family of transcription factors. Genome Biol. 6, 246 (2005).","journal-title":"Genome Biol"},{"key":"1600_CR15","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.neuroscience.2016.10.055","volume":"340","author":"X Xu","year":"2017","unstructured":"Xu, X. et al. AP-2alpha and AP-2beta regulate dorsal interneuron specification in the spinal cord. Neuroscience 340, 232\u2013242 (2017).","journal-title":"Neuroscience"},{"key":"1600_CR16","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1101\/gad.11.15.1938","volume":"11","author":"M Moser","year":"1997","unstructured":"Moser, M. et al. Enhanced apoptotic cell death of renal epithelial cells in mice lacking transcription factor AP-2beta. Genes Dev. 11, 1938\u20131948 (1997).","journal-title":"Genes Dev."},{"key":"1600_CR17","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/MCD.0000000000000222","volume":"27","author":"D Nyboe","year":"2018","unstructured":"Nyboe, D. et al. A study of familial Char syndrome involving the TFAP2B gene with a focus on facial shape characteristics. Clin. Dysmorphol. 27, 71\u201377 (2018).","journal-title":"Clin. Dysmorphol."},{"key":"1600_CR18","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/75578","volume":"25","author":"M Satoda","year":"2000","unstructured":"Satoda, M. et al. Mutations in TFAP2B cause Char syndrome, a familial form of patent ductus arteriosus. Nat Genet 25, 42\u201346 (2000).","journal-title":"Nat Genet"},{"key":"1600_CR19","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1002\/ijc.22648","volume":"120","author":"JM Pellikainen","year":"2007","unstructured":"Pellikainen, J. M. & Kosma, V. M. Activator protein-2 in carcinogenesis with a special reference to breast cancer\u2013a mini review. Int. J. Cancer 120, 2061\u20132067 (2007).","journal-title":"Int. J. Cancer"},{"key":"1600_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-13-89","volume":"13","author":"L Fu","year":"2014","unstructured":"Fu, L. et al. TFAP2B overexpression contributes to tumor growth and a poor prognosis of human lung adenocarcinoma through modulation of ERK and VEGF\/PEDF signaling. Mol. Cancer 13, 89 (2014).","journal-title":"Mol. Cancer"},{"key":"1600_CR21","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.ygyno.2018.03.057","volume":"149","author":"H Wu","year":"2018","unstructured":"Wu, H. & Zhang, J. Decreased expression of TFAP2B in endometrial cancer predicts poor prognosis: a study based on TCGA data. Gynecol Oncol. 149, 592\u2013597 (2018).","journal-title":"Gynecol Oncol"},{"key":"1600_CR22","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/labinvest.2017.106","volume":"98","author":"M Raap","year":"2017","unstructured":"Raap, M. et al. Lobular carcinoma in situ and invasive lobular breast cancer are characterized by enhanced expression of transcription factor AP-2\u03b2. Lab. Invest. 98, 117\u2013129 (2017).","journal-title":"Lab. Invest."},{"key":"1600_CR23","doi-asserted-by":"crossref","first-page":"8046","DOI":"10.18632\/oncotarget.3508","volume":"6","author":"Y Xiao","year":"2015","unstructured":"Xiao, Y. et al. Ku80 cooperates with CBP to promote COX-2 expression and tumor growth. Oncotarget 6, 8046\u20138061 (2015).","journal-title":"Oncotarget"},{"key":"1600_CR24","first-page":"940","volume":"16","author":"C Xie","year":"2018","unstructured":"Xie, C. et al. Cyclooxygenase-2 induces angiogenesis in pancreatic cancer mediated by prostaglandin E2. Oncol Lett. 16, 940\u2013948 (2018).","journal-title":"Oncol Lett"},{"key":"1600_CR25","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-18-0427","author":"Y Zhang","year":"2018","unstructured":"Zhang, Y. et al. Cyclooxygenase-2 inhibition potentiates the efficacy of vascular endothelial growth factor blockade and promotes an immune stimulatory microenvironment in preclinical models of pancreatic cancer. Mol. Cancer Res. https:\/\/doi.org\/10.1158\/1541-7786.MCR-18-0427 (2018).","journal-title":"Mol. Cancer Res"},{"key":"1600_CR26","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.biopha.2018.03.066","volume":"102","author":"H Gungor","year":"2018","unstructured":"Gungor, H., Ilhan, N. & Eroksuz, H. The effectiveness of cyclooxygenase-2 inhibitors and evaluation of angiogenesis in the model of experimental colorectal cancer. Biomed. Pharmacother. 102, 221\u2013229 (2018).","journal-title":"Biomed. Pharmacother"},{"key":"1600_CR27","doi-asserted-by":"publisher","first-page":"465","DOI":"10.2147\/CMAR.S157823","volume":"10","author":"C Jiang","year":"2018","unstructured":"Jiang, C. et al. Clinical behaviors of rare variants of papillary thyroid carcinoma are associated with survival: a population-level analysis. Cancer Manag. Res. 10, 465\u2013472 (2018).","journal-title":"Cancer Manag. Res."},{"key":"1600_CR28","doi-asserted-by":"publisher","first-page":"S114","DOI":"10.4103\/0973-1482.163675","volume":"14","author":"S Selemetjev","year":"2018","unstructured":"Selemetjev, S., Savin, S., Paunovic, I., Tatic, S. & Cvejic, D. Concomitant high expression of survivin and vascular endothelial growth factor-C is strongly associated with metastatic status of lymph nodes in papillary thyroid carcinoma. J. Cancer Res. Ther. 14, S114\u2013S119 (2018).","journal-title":"J. Cancer Res. Ther."},{"key":"1600_CR29","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ebiom.2017.10.024","volume":"25","author":"M Yoshihara","year":"2017","unstructured":"Yoshihara, M. et al. Restricted presence of POU6F2 in human corneal endothelial cells uncovered by extension of the promoter-level expression atlas. EBioMedicine 25, 175\u2013186 (2017).","journal-title":"EBioMedicine"},{"key":"1600_CR30","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1074\/jbc.RA118.005527","volume":"294","author":"S Hara","year":"2019","unstructured":"Hara, S. et al. Transcription factor TFAP2B up-regulates human corneal endothelial cell-specific genes during corneal development and maintenance. J. Biol. Chem. 294, 2460\u20132469 (2019).","journal-title":"J. Biol. Chem."},{"key":"1600_CR31","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.3892\/ijo.2017.3886","volume":"50","author":"KW Ren","year":"2017","unstructured":"Ren, K. W. et al. Quercetin nanoparticles display antitumor activity via proliferation inhibition and apoptosis induction in liver cancer cells. Int. J. Oncol. 50, 1299\u20131311 (2017).","journal-title":"Int. J. Oncol."},{"key":"1600_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s13041-015-0118-x","volume":"8","author":"K Jin","year":"2015","unstructured":"Jin, K. et al. Tfap2a and 2b act downstream of Ptf1a to promote amacrine cell differentiation during retinogenesis. Mol. Brain 8, 28 (2015).","journal-title":"Mol. Brain"},{"key":"1600_CR33","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1152\/physiolgenomics.00077.2018","volume":"51","author":"M Caspers","year":"2019","unstructured":"Caspers, M. et al. Metabolic fitness in relation to genetic variation and leukocyte DNA methylation. Physiol Genomics 51, 12\u201326 (2019).","journal-title":"Physiol Genomics"},{"issue":"436","key":"1600_CR34","doi-asserted-by":"publisher","first-page":"eaan3464","DOI":"10.1126\/scitranslmed.aan3464","volume":"10","author":"Jordan A. Krall","year":"2018","unstructured":"Krall, J. A. et al. The systemic response to surgery triggers the outgrowth of distant immune-controlled tumors in mouse models of dormancy. Sci. Transl. Med. 10, https:\/\/doi.org\/10.1126\/scitranslmed.aan3464 (2018).","journal-title":"Science Translational Medicine"},{"key":"1600_CR35","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1093\/jnci\/djy017","volume":"110","author":"K Strasser-Weippl","year":"2018","unstructured":"Strasser-Weippl, K. et al. Effects of celecoxib and low-dose aspirin on outcomes in adjuvant aromatase inhibitor-treated patients: CCTG MA.27. J. Natl. Cancer Inst. 110, 1003\u20131008 (2018).","journal-title":"J. Natl. Cancer Inst."},{"key":"1600_CR36","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/nrg1315","volume":"5","author":"WW Wasserman","year":"2004","unstructured":"Wasserman, W. W. & Sandelin, A. Applied bioinformatics for the identification of regulatory elements. Nat. Rev. Genet. 5, 276\u2013287, https:\/\/doi.org\/10.1038\/nrg1315 (2004).","journal-title":"Nat. Rev. Genet."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-1600-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-1600-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-1600-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T17:04:09Z","timestamp":1671210249000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-1600-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,21]]},"references-count":36,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,6]]}},"alternative-id":["1600"],"URL":"https:\/\/doi.org\/10.1038\/s41419-019-1600-7","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,21]]},"assertion":[{"value":"11 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"397"}}